Antisense modulation of vascular endothelial growth factor receptor-1 expression

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of vascular endothelial growth factor receptor-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding vascular endothelial growth factor receptor-1. Methods of using these compounds for modulation of vascular endothelial growth factor receptor-1 expression and for treatment of diseases associated with expression of vascular endothelial growth factor receptor-1 are provided.

What is claimed is:  
     
         1 . An antisense compound consisting of SEQ ID NO: 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 44, 45, 46, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 67, 68, 70, 71, 72, 73, 74, 75, 76, 78, 79, 81, 83, 87, 88, 90, 91, 92, 93, 95, 96, 97, 98, 99, 69, 82, 85, 102, 103, 104, 105, 107, 108, 109, 111, 113, 114, 115, 116, 119, 120, 121, 122, 124, 125, 126, 127, 128, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 149, 150, 151, 152, 153 or 154 which inhibits the expression of vascular endothelial growth factor receptor-1.  
     
     
         2 . The compound of  claim 1  which is an antisense oligonucleotide.  
     
     
         3 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.  
     
     
         4 . The compound of  claim 3  wherein the modified internucleoside linkage is a phosphorothioate linkage.  
     
     
         5 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified sugar moiety.  
     
     
         6 . The compound of  claim 5  wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.  
     
     
         7 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified nucleobase.  
     
     
         8 . The compound of  claim 7  wherein the modified nucleobase is a 5-methylcytosine.  
     
     
         9 . The compound of  claim 2  wherein the antisense oligonucleotide is a chimeric oligonucleotide.  
     
     
         10 . A composition comprising the compound of  claim 1  and a pharmaceutically acceptable carrier or diluent.  
     
     
         11 . The composition of  claim 10  further comprising a colloidal dispersion system.  
     
     
         12 . The composition of  claim 10  wherein the antisense compound is an antisense oligonucleotide.  
     
     
         13 . A method of inhibiting the expression of vascular endothelial growth factor receptor-1 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of  claim 1  so that expression of vascular endothelial growth factor receptor-1 is inhibited.